Serum Levels of Cytokines and Soluble Cytokine Receptors in Patients with Metastatic Renal Cell Carcinoma or Malignant Melanoma Receiving IL-2/Interferon-α Combination Therapy
| Autor: | Harald Gallati, Steiner Aamdal, Sophie D. Fosså, Bjørn Naume |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
medicine.medical_specialty
Time Factors medicine.medical_treatment Alpha interferon Clinical Trials Phase II as Topic Renal cell carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Receptors Cytokine Carcinoma Renal Cell Melanoma Interferon alfa Kidney business.industry Interferon-alpha Hematology General Medicine Immunotherapy medicine.disease Cytokine Endocrinology medicine.anatomical_structure Oncology Cytokines Interleukin-2 business medicine.drug |
| Zdroj: | Acta Oncologica. 34:599-603 |
| ISSN: | 1651-226X 0284-186X |
| Popis: | Elevated serum levels of soluble tumour necrosis factor receptor (sTNFR-55) and (at a lesser degree) of sTNFR-75 were found in most of the patients with metastatic renal cell carcinoma (RCC) or malignant melanoma (MM) before immunotherapy and with further increase during treatment (intravenous infusions of interleukin-2 [IL-2] and subcutaneous interferon-alpha [IFN-alpha]). In the majority of the patients with MM the pretreatment serum levels of IL-2 and soluble IL-2 receptor (sIL-2R) were increased, whereas fewer patients with RCC presented with increased serum levels of IL-2 and sIL-2R. Twelve days' treatment with IL-2/IFN-alpha, with a rest on days 6 and 7, resulted in a consistent further increase in the serum levels of sIL-2R and sTNFRs. In most patients the increase of sIL-2R and sTNFRs lasted for at least 3 weeks after treatment discontinuation. The clinical significance of the increase remains unknown. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|